A kit containing a solution of boronic acid adducts of technetium-99 m dioxime complexes; and hydroxypropyl gamma cyclodextrin to maintain the solution free of particulate matter originating from the formulation.
|
5. In an improved kit for myocardial diagnosis of a patient with suspected coronary artery diseases using rest and stress techniques said kit; having
a) a first container containing lyophilized ingredients containing 1 to 3 mg cyclohexanedione dioxime; 1 to 3 mg methyl boronic acid; 8 to 10 mg citric acid; 5 to 10 mg sodium chloride; and 0.030 to 0.060 mg stannous chloride (SnCl2); and b) a second container containing 1 to 3 ml technetium tc-99 m in physiological saline; wherein the improvement comprises: 30 to 50 mg hydroxypropyl gamma cyclodextrin added to said first container. 1. In an improved kit for myocardial diagnosis of a patient with suspected coronary artery diseases using rest and stress techniques, said kit having
(a) a first container containing lyophilized ingredients; and (b) a second container containing technetium tc-99 m;
wherein said first container contains 5 to 15 mg sodium chloride, or sodium bromide; 1 to 3 mg of boronic acid derivative, or compounds which can react in situ to form a boronic acid derivative, having the formula ##STR5## or a pharmaceutically acceptable salt thereof, wherein R3 is hydroxy, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aloxy, carboxyalkyl, carboxyalkenyl, hydroxyalkyl, hydroxalkenyl, alkoxyalkyl, aloxy-alkenyl, haloalkyl, haloalkenyl, aryl, arylalkyl, or R4 R5 N-alkyl and R4 and R5 are each independently hydrogen, alkyl, or arylalkyl, or R4 and R5 when taken together with nitrogen atom to which they are attached form a 5 or 6-membered nitrogen containing heterocycle, and R7 is hydrogen, alkyl or aryl; 1 to 3 mg of a dioxime having the formula ##STR6## or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently hydrogen, halogen, alkyl, aryl, amino or a 5 or 6-membered nitrogen or oxygen containing heterocycle, or together R2 and R3 are --(CH2 R9)-- wherein n is 3, 4, 5, or 6 and R8 and R9 are each independently hydrogen or alkyl; 0.03 to 0.06 mg stannous chloride; 1 to 3 mg pentetic acid; and 8 to 10 mg citric acid; and said second container contains 1 to 3 ml of technetium tc-99 m in physiological saline containing 10 to 100 mCi; wherein the improvement comprises: 30 to 50 mg hydroxypropyl gamma cyclodextrin added to said first container. 2. The kit for myocardial diagnosis of a patient according to
dimethyl glyoxime, 1,2-cyclohexanedione dioxime, 1,2-ethanedione dioxime, α-furyldioxime, 1, 2-cyclopentanedione dioxime and 3-methyl-1, 2-cyclopentanedione dioxime.
3. The kit for myocardial diagnosis of a patient according to
B-alkyl, B-alkoxy, B-benzyl and B-cycloalkyl.
4. The kit for myocardial diagnosis of a patient according to
99m tc (chlorine) (dimethyl glyoxime)3 methoxy boron; 99m tc (chlorine) (dimethyl glyoxime)3 hydroxy boron; 99m tc (chlorine) (dimethyl glyoxime)3 ethoxy boron; 99m tc (chlorine) (dimethyl glyoxime)3 propyloxy boron; 99m tc (chlorine) (dimethyl glyoxime)3 hexyloxy boron; 99m tc (chlorine) (dimethyl glyoxime)3 1-methylpropyl boron; 99m tc (bromine) (dimethyl glyoxime)3 butyl boron; 99m tc (iodine) (dimethyl glyoxime)3 butyl boron; 99m tc (fluorine) (dimethyl glyoxime)3 butyl boron; 99m tc (chlorine) (dimethyl glyoxime)3 3-(4-morpholinyl)propyl boron; 99m tc (chlorine) (dimethyl glyoxime)3 2-phenylethyl boron; 99m tc (chlorine) (1,2-cyclohexanedione dioxime)3 methyl boron; and 99m tc (chlorine) (dimethyl glyoxime)3 4-formylphenyl boron. |
|||||||||||||||||||||||||||||||
1. Field of the Invention
The present invention relates to imaging agents. More particularly, the invention relates to imaging agents for imaging the myocardium in patients with suspected coronary artery diseases using rest and stress techniques.
2. Reported Developments
U.S. Pat. No. 4,705,849 discloses boronic acid adducts of technetium-99 m dioxime complexes for imaging the myocardium, hepatobiliary system, brain and blood pool in humans and other mammalian species. One of these complexes is used in a kit for imaging the myocardium, and sold under the trademark CARDIOTEC®.
The kit comprises a 5 ml reaction vial which contains a sterile, nonpyrogenic, lyophilized formulation of: 2.0 mg cyclohexanedione dioxime;
2.0 mg methyl boronic acid;
2.0 mg pentetic acid;
9.0 mg citric acid;
100.0 mg sodium chloride;
50.0 mg gamma cyclodextrin; and
0.058 mg (maximum) total tin expressed as stannous
chloride (SnCl2), 0.020 mg (minimum) stannous
chloride (SnCl2).
To the 5 ml reaction vial, containing the lyophilized formulation, 1 ml sodium pertechnetate Tc-99 m injection is added containing 370 to 3,700 MBq (10-100 mCi) to obtain a solution which is then heated at 100° C. for 15 minutes to obtain the diagnostic agent Technetium Tc-99 m Teboroxime.
The diagnostic agent has been used by health care professionals over several years and it has been found useful in distinguishing normal from abnormal myocardium in patients with suspected coronary artery diseases using rest and stress techniques.
The CARDIOTEC® kit contains a package insert instructing the diagnosticians to visually inspect the reconstituted formulation subsequent to the addition of the pertechnetate Tc-99 m into the reaction vial and the heating step. The formulation is to be used only if the solution is clear to slightly opalescent and free of particulate matter and discoloration.
The occurrence of particulate matter formation and discoloration of the diagnostic agent necessitated an investigation for finding a cause thereof. During the course of the investigation the solution was filtered to remove the particulate matter, which appeared to be successful. However, upon further investigation it was found that the problem of particulate matter formation and discoloration cannot be eliminated by filtration. Although immediately after filtration the solution is clear, the turbidity and discoloration reappear after a period of time necessitating re-filtration or discarding of the solution.
Thus, the additional step of filtration in producing the diagnostic agent was impractical, as it was cumbersome and inconvenient to the diagnosticians mainly for the reasons that: diagnostic facilities are not ordinarily equipped with such filtration devices having adequate radioactive shielding and the necessity to perform the filtration procedure immediately before use as it was not effective over the shelf-life of the reconstituted product.
Applicants in conducting extensive studies with the boronic acid adducts of technetium-99 m dioxime complexes disclosed in U.S. Pat. No. 4,705,849, which patent is incorporated herein by reference in its entirety, found a solution to the problems of particulate matter formation and discoloration.
Accordingly, the object of the present invention is to provide improved solutions of boronic acid adducts of technetium-99 m dioxime complexes for mycocardial infusion, in which no particulate matter is formed or discoloration occurs upon the injection of pertechnetate Tc-99 m into the reaction vial containing the lyophilized ingredients or during the shelf-life of the so-produced diagnostic agent formulation.
We have surprisingly discovered that the addition of hydroxypropyl gamma cyclodextrins, preferably 2-hydroxypropyl gamma cyclodextrin which replaces the gamma cyclodextrin used in the CARIDIOTEC® formulation of the lyophilized ingredients in the reaction vial, provides clear solutions when the lyophilized ingredients are reconstituted by the addition of pertechnetate Tc-99 m. Accordingly, the present invention comprises a kit having (a) first container such as a vial which contains lyophilized ingredients and (b) second container such as a vial or syringe which contains sodium pertechnetate Tc-99 m.
(a) First container, such as a vial preferably contains:
1 to 3 mg cyclohexanedione dioxime;
1 to 3 mg methyl boronic acid;
1 to 3 mg pentetic acid;
8 to 10 mg citric acid;
5 to 10 mg sodium chloride;
30 to 50 mg hydroxypropyl gamma cyclodextrin; and
0.030 to 0.060 mg stannous chloride (SnCl2).
(b) Second container, such as a vial contains:
1 to 3 ml pertechnetate Tc-99 m having 370 to 3,700 MBq (10-100 mCi) in physiological saline or derived from generator sources.
In preparing Technetium Tc-99 m Teboroxime the sodium pertechnetate Tc-99 m is added from the second container to the first container which contains the lyophilized ingredients to provide a sterile mixture, swirling the contents of the first container and heating the same at about 100° C. for 5 to 15 minutes to obtain a solution, and cooling the solution which is then ready for parenteral administration to a patient.
The diagnostic formulation obtained has been tested and found to be free of particulate matter and discoloration for at least six hours without filtration or other means to eliminate the presence of particulate matter or the appearance of discoloration.
In another aspect the present invention is directed to a method for providing a radiopharmaceutical kit, the method comprising:
(1) providing a first container, such as a vial containing a solution of
1 to 3 mg cyclohexanedione dioxime;
1 to 3 mg methyl boronic acid;
1 to 3 mg pentetic acid;
8 to 10 mg citric acid;
5 to 10 mg sodium chloride;
30 to 50 mg hydroxypropyl gamma cyclodextrin; and
0.030 to 0.060 mg stannous chloride (SnCl2).
(2) lyophilizing the content of the first container;
(3) providing a second container containing;
1 to 5 ml pertechnetate Tc-99 m having 370 to 3,700 MBq (10-100 mCi) in physiological saline or from generator sources;
(4) injecting the content of the second container into the first container to obtain a mixture thereof;
(5) heating the solution at about 100°C to obtain a solution thereof; and
(6) cooling the solution to room temperature for administration to a patient.
The formulation of the present invention for myocardial diagnosis utilizes boric acid adducts of technetium-99 m dioxime complexes of formula I:
99m TcX(Y)3 Z I
wherein X is an anion;
Y is vicinal dioxime of formula II; ##STR1## or a pharmaceutically acceptable salt thereof; R1 and R2 are independently, hydrogen, halogen, alkyl, aryl, amino or a 5 or 6-membered nitrogen or oxygen containing heterocycle, or together
R1 and R2 are-(CR8 R9)n
wherein n is 3 to 6 and
R8 and R9 are independently hydrogen or alkyl; and Z is a boron derivative of formula III:
B--R3 III
wherein
R3 is hydroxy, alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxy, carboxyalkyl, carboxyalkenyl, hydroxyalkyl, hydroxyalkenyl, alkoxyalkyl, alkoxyalkenyl, haloalkyl, haloalkenyl, aryl, arylalkyl or (R4 R5 N)-alkyl and R4 and R5 are each independently hydrogen, alkyl, or arylalkyl, or R4 and R5 when taken together with the nitrogen atom to which they are attached form a 5 or 6-membered nitrogen containing heterocycle.
The definition of radicals and moieties are as follows.
The terms "alkyl" and "alkoxy" refer to both straight and branched chain groups. Those groups having 1 to 10 carbon atoms are preferred.
The term "alkenyl" refers to both straight and branched chain groups. Those groups having 2 to 10 carbon atoms are preferred.
The term "aryl" refers to phenyl and substituted phenyl. Preferred are phenyl and phenyl substituted with 1, 2 or 3 alkyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, alkoxyalkyl, halogen, amino, hydroxy, or formyl groups. Additional exemplary aryl groups for the instance wherein R3 is aryl include 3-(5-dimethylamino-1-naphthalensulfonyl-amino)phenyl, 3-[4-[3'-phenyl-2'pyrazolin-1,1'-yl]benzene-sulfonyl-amino]phenyl, 3-(pyrenesulfamido)-phenyl, 3-[4-(4-dimethylamino- 1-naphthylazo)-3 -(methoxyphenyl-sulfamido)] phenyl, 3-[4-(4-dimethylamino-1-phenylazo) phenylthioureido] phenyl.
Preferred "cycloalkyl" and "cycloalkenyl" groups are those having 5, 6 or 7 carbon atoms. The terms include those groups substituted with alkyl, alkoxyl, aryl, carboxyalkyl, arylalkyl or (R4 R5 N)-alkyl groups.
The terms "halide", "halo" and "halogen" refer to fluorine, chlorine, bromine and iodine.
The expression "5 or 6-membered nitrogen containing heterocycle" refers to all 5 and 6-membered rings containing at least one nitrogen atom. Exemplary aliphatic groups are dihydro derivatives of a compound having the formula ##STR2## wherein m is 0 or 1 and A is O, N--R6 or CH--R6 wherein R6 is hydrogen, alkyl, aryl or arylalkyl. Such groups include pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, 4-alkylpiperazinyl, 4-alkylpiperidinyl, and 3-alkylpyrrolidinyl groups. Also included within the expressions "5 or 6 membered nitrogen containing heterocycle" are aromatic groups. Exemplary aromatic groups are pyrrolyl, imidazolyl, oxazolyl, pyrazolyl, pyridinyl, and pyrimidinyl groups. The above groups can be linked via hetero atom or carbon atom.
The expression "5 or 6-membered nitrogen or oxygen containing heterocycle" refers to all 5 and 6-membered rings containing at least one nitrogen or oxygen atom. Exemplary groups are those described above under the definition of the expression "5 or 6-membered nitrogen containing heterocycle". Additional exemplary groups are 1,4-dioxanyl and furanyl.
Preparation of the complexes
The complexes are preferably prepared by using technetium-99 m in the form of the pertechnetate ion which is commercially available. Alternatively, the pertechnetate ion can be prepared as described in U.S. Pat. Nos. 3,369,121 and 3,920,995. The generators are eluted with a saline solution to obtain the sodium salt of the pertechnetate ion.
The salt of pertechnetate ion is combined with a source of anion, a boronic acid derivative of the formula ##STR3## or a pharmaceutically acceptable salt thereof, wherein
R7 is hydrogen, alkyl or aryl, and
dioxime having the formula ##STR4## or a pharmaceutically acceptable salt thereof.
The source of an anion is preferably sodium chloride in a concentration of from about 0.1 to about 0.5 molar.
The boronic acid derivative should be present in a concentration range of from about 5 to about 200 millimolar; while the dioxime should be present in the concentration range of from about 9 to about 43 millimolar.
The reaction mixture should also contain a reducing agent. Stannous ion is the preferred reducing agent, and can be introduced in the form of a stannous salt such as a stannous halide (e.g., stannous chloride or stannous fluoride). The reducing agent should be present in a concentration of about 1.5 micromolar to 6.6 millimolar.
Complexing or chelating agents as well as accelerators or catalysts known in the art may also be used in preparing the diagnostic agent of the present invention.
Illustrative examples of the complexes include:
99m Tc (chlorine) (dimethyl glyoxime)3 methoxy boron;
99m Tc (chlorine) (dimethyl glyoxime)3 ethoxy boron;
99m Tc (chlorine) (dimethyl glyoxime)3 hydroxy boron;
99m Tc (chlorine) (dimethyl glyoxime)3 propyloxy boron;
99m Tc (chlorine) (dimethyl glyoxime)3 hexyloxy boron;
99m Tc (chlorine) (dimethyl glyoxime)3 1-methylpropyl boron;
99m Tc (bromine) (dimethyl glyoxime)3 butyl boron;
99m Tc (iodine) (dimethyl glyoxime)3 butyl boron;
99m Tc (fluorine) (dimethyl glyoxime)3 butyl boron;
99m Tc (chlorine) (dimethyl glyoxime)3 3-(4-morpholinyl)propyl boron;
99m Tc (chlorine) (dimethyl glyoxime)3 2-phenylethyl boron;
99m Tc (chlorine) (1,2-cyclohexanedione dioxime)3 methyl boron; and
99m Tc (chlorine) (dimethyl glyoxime)3 4-formylphenyl boron.
Illustrative of the preparation of the diagnostic agent is shown in Examples 1 and 2.
99m Tc (chlorine)(1,2-cyclohexanedionedioxime)3, 3-(1-piperidinyl)propyl boron.
Into a 5 ml siliconized vial were measured 0.5 mg of 1,2-cyclohexanedione dioxime in 0.1 ml of ethanol, 1.0 mg of 3-(1-piperidinyl)propane boronic acid monohydrochloride, 0.2 ml of saturated sodium chloride, 10 mg of citric acid, 40 mg of hydroxypropyl gamma cyclodextrin and 50 μl of saturated stannous pyrophosphate.
Sodium pertechnetate Tc-99 m in physiological saline (0.2 ml) was added to this vial which was then heated at 100°C for 5 minutes yielding 84% of the title complex.
The solution remained clear without containing particulate matter for more than 6 hours after preparation.
99m Tc (chlorine)(1,2-cyclohexanedione dioxime)3 methyl boron.
Into a 5 ml serum vial were measured 2.0 mg of 1,2-cyclohexanedione dioxime, 2.0 mg of methane boronic acid, 10 mg of citric acid, 10 mg of sodium chloride, 1.0 mg of diethylenetriamine pentaacetic acid, 45 mg of hydroxypropyl gamma cyclodextrin, 50 micrograms of SnCl2 and 0.5-3 μl of concentrated hydrochloric acid.
Sodium pertechnetate Tc-99 m in physiological saline (0.5 ml) was added to the vial which was then heated at 100°C for 5 minutes yielding 85% of the title complex.
The solution remained clear without containing particulate matter for more than 6 hours after preparation.
Testing of the diagnostic agent
Technetium Tc-99 m decays by isometric transition with a physical half-life of 6.02 hours. The fractions that remain at selected intervals after the initial calibration are shown in Table I.
| TABLE I |
| ______________________________________ |
| Physical Decay Chart: Tc-99m half-life 6.02 hours |
| Fraction Fraction |
| Hours Remaining Hours Remaining |
| ______________________________________ |
| 0* 1.000 7 0.447 |
| 1 0.891 8 0.398 |
| 2 0.794 9 0.355 |
| 3 0.708 10 0.316 |
| 4 0.631 11 0.282 |
| 5 0.562 12 0.251 |
| 6 0.501 |
| ______________________________________ |
| *Calibration time |
Following intravenous administration in normal subjects, Technetium Tc-99 m Teboroxime was rapidly cleared from the circulation. Table II approximates the effective clearance of Technetium Tc-99 m Teboroxime from the heart and liver.
| TABLE II |
| ______________________________________ |
| Time Heart* Liver |
| ______________________________________ |
| 5 min 2.3% 23% |
| 10 min 1.7% 33% |
| 15 min 1.5% 32% |
| 20 min 1.3% 27% |
| 1 hr 1.1% 24% |
| 2 hr 0.8% 18% |
| 4 hr 0.6% 17% |
| ______________________________________ |
| *Peak heart uptake occurs within 2 min. |
The estimated absorbed radiation doses to organs and tissues of an average subject (70 kg) from intravenous injection totaling 1850 MBq (50 millicuries) of Technetium Tc-99 m Teboroxime are shown in Table III.
| TABLE III |
| ______________________________________ |
| Estimated Absorbed Radiation Doses Absorbed Radiation Dose |
| Tissue mGy/1650 MBq |
| Rads/50 mCi |
| ______________________________________ |
| Brain 6.30 0.63 |
| Gallbladder Wall |
| 48.85 4.89 |
| Small Intestine 33.85 3.39 |
| Upper Large Intestine |
| 61.50 6.15 |
| Lower Large Intestine |
| 43.60 4.36 |
| Heart Wall 10.10 1.01 |
| Kidneys 10.10 1.01 |
| Liver 31.00 3.10 |
| Lungs 14.00 1.40 |
| Spleen 7.45 0.75 |
| Thyroid 5.35 0.54 |
| Ovaries 18.05 1.81 |
| Testes 5.20 0.52 |
| Red Marrow 8.30 0.83 |
| Urinary Bladder Wall |
| 13.70 1.37 |
| Total Body 8.30 0.83 |
| ______________________________________ |
Post-reconstitution appearance of CARDIOTEC® containing gamma cyclodextrin.
An investigation was conducted to determine the size, identity and cause of particles in reconstituted CARDIOTEC® containing gamma cyclodextrin. The investigation revealed that shortly after reconstitution a fine haze of suspended particles appeared which were identified as gamma cylcodextrin using FT-IR. Stereomicroscopic examination revealed that a colorless residue, identified as gamma cyclodextrin, consisted of small clusters of particles, ranging in size from 10 to 40 μm. Individual particles ranged from 0 to 10am, with a few as large as 20 μm.
Visual appearance of CARDIOTEC® formulated with gamma cyclodextrin vs. hydroxypropyl gamma cyclodextrin.
Four batches of CARDIOTEC® solutions were prepared: batches 100 and 200 were formulated with gamma cyclodextrin; and batches 300 and 400 were formulated with hydroxypropyl gamma cyclodextrin. The solutions were visually observed with the following results shown in Table IV.
| TABLE IV |
| ______________________________________ |
| Post-reconstitution appearance of CARDIOTEC ® containing gamma |
| cyclodextrin vs. hydroxypropyl gamma cyclodextrin (comparative test). |
| Hydroxy Propyl Gamma |
| Gamma Cyclodextrin |
| Cyclodextrin |
| Batch No. |
| Visual Appearance |
| Batch No. Visual Appearance |
| ______________________________________ |
| 100 Opalescent/Suspended |
| 300 Clear |
| Particles Particle Free |
| 200 Clear/Slightly Opalescent |
| 400 Clear |
| Few Undissolved Particle Free |
| Particles |
| ______________________________________ |
The visual appearance test of reconstituted CARDIOTEC® is user subjective with no numerical reference point. The present test under this heading describes a semi-quantitative alternate method for the determination of the appearance of reconstituted vials of CARDIOTEC® based on the British Pharmacopoeia clarity of solution test. (British Pharmacopoeia 1993, Volume II, Appendix IV B, pp. A107-108.)
The British Pharmacopoeia method for clarity measures the degree of opalescence and expresses it in terms of four reference suspensions (I-IV). Reference suspension I is the least opalescent and reference suspension IV is the most opalescent. A pooled sample of CARDIOTEC® is assigned a number by comparing the appearance of the sample to the appearance of the reference suspensions. Samples are reported as less than (<) the reference suspension number which is more opalescent than the sample. A liquid is considered clear if its clarity is the same as that of water, or if its opalescence is not more pronounced than that of reference suspension I.
The British Pharmacopoeia test (≈15 mL total volume) is performed using 16 pooled vials of CARDIOTEC® reconstituted with 1 mL of saline. A British Pharmacopoeia value of less than or equal to I (≦) would indicate a clear solution while a larger reported British Pharmacopoeia value would indicate a greater degree of opalescence.
The result of comparative testing is shown in Table V.
Appearance Results on Batches of CARDIOTEC® Formulated with Gamma Cyclodextrin vs. Hydroxy Propyl-Gamma Cyclodextrin for up to Six Hours after Reconstitution, when Tested According to the British Pharmacopoeia Clarity Test.
| ______________________________________ |
| Gamma Cyclodextrin |
| Hydroxy Propyl-Gamma Cyclodextrin |
| Batch No. |
| Visual Appearance |
| Batch No. Visual Appearance* |
| ______________________________________ |
| 100 >III 300 <I, clear |
| 200 >III 400 ≦I, clear |
| -- -- 500 ≦I, clear |
| ______________________________________ |
| *Method: BP Clarity Test (16 vials, 1.0 mL reconstitution volume) |
Having described the invention, it will be apparent to those skilled in the art that various modification may be made without departing from the spirit thereof Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the claims that follow.
Zodda, Julius P., Monteferrante, Jo Anna, Schramm, Ernest, Newborn, Margaret, Katona, Thomas
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 4705849, | Apr 15 1985 | BRACCO INTERNATIONAL B V | Boronic acid adducts of technetium-99m dioxime complexes |
| 4714605, | Oct 14 1986 | BRACCO INTERNATIONAL B V | Technetium-99m labeled dioxime complexes |
| 4727064, | Apr 25 1984 | The United States of America as represented by the Department of Health; United States of America as represented by the Secretary of the Department of Health and Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| 4871836, | Oct 13 1987 | BRACCO INTERNATIONAL B V | Boronic acid adducts of rhenium and radioactive isotopes of rhenium dioxime complexes |
| 5069900, | Aug 28 1989 | BRACCO INTERNATIONAL B V | Boronic acid adducts of technetium-99m dioxime-imine complexes |
| 5070081, | Apr 20 1988 | NATIONAL RESEARCHJ COUNCIL CANADA CONSEIL NATIONAL DE RECHERCES CANADA | Inclusion complexes of cyclodextrins by agglomeration |
| 5112595, | Dec 21 1990 | MALLINCKRODT MEDICAL, INC A CORPORATION OF DE | 99MTC(III) myocardial imaging agents and method of use |
| 5118797, | Aug 28 1989 | BRACCO INTERNATIONAL B V | Rhenium tris dioxime complexes |
| 5183653, | Apr 13 1990 | BRACCO INTERNATIONAL B V | Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds |
| 5300280, | Feb 14 1992 | Mallinckrodt Medical, Inc.; MALLINCKRODT MEDICAL, INC | Stabilized radiopharmaceutical kits |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jul 28 1999 | Bracco Research USA | (assignment on the face of the patent) | / | |||
| Jul 28 1999 | SCHRAMM, ERNST | Bracco Research, USA | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010138 | /0271 | |
| Jul 28 1999 | NEWBORN, MARGARET | Bracco Research, USA | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010138 | /0271 | |
| Jul 28 1999 | ZODDA, JULIUS P | Bracco Research, USA | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010138 | /0271 | |
| Jul 28 1999 | KATONA, THOMAS | Bracco Research, USA | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010138 | /0271 | |
| Jul 28 1999 | MONTEFERRANTE, JO ANNA | Bracco Research, USA | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010138 | /0271 | |
| Oct 18 1999 | BAUDET, JEAN-PIERRE | Clear Image Concepts LLC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010426 | /0721 | |
| Dec 17 2001 | BRACCO RESEARCH USA INC | BRACCO DIAGNOSTICS INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 012735 | /0974 |
| Date | Maintenance Fee Events |
| Oct 27 2003 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Nov 19 2003 | REM: Maintenance Fee Reminder Mailed. |
| Nov 20 2003 | REM: Maintenance Fee Reminder Mailed. |
| Nov 25 2003 | ASPN: Payor Number Assigned. |
| Nov 02 2007 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Nov 17 2010 | ASPN: Payor Number Assigned. |
| Nov 17 2010 | RMPN: Payer Number De-assigned. |
| Nov 02 2011 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
| Date | Maintenance Schedule |
| May 02 2003 | 4 years fee payment window open |
| Nov 02 2003 | 6 months grace period start (w surcharge) |
| May 02 2004 | patent expiry (for year 4) |
| May 02 2006 | 2 years to revive unintentionally abandoned end. (for year 4) |
| May 02 2007 | 8 years fee payment window open |
| Nov 02 2007 | 6 months grace period start (w surcharge) |
| May 02 2008 | patent expiry (for year 8) |
| May 02 2010 | 2 years to revive unintentionally abandoned end. (for year 8) |
| May 02 2011 | 12 years fee payment window open |
| Nov 02 2011 | 6 months grace period start (w surcharge) |
| May 02 2012 | patent expiry (for year 12) |
| May 02 2014 | 2 years to revive unintentionally abandoned end. (for year 12) |